Table 1.
Summary of anatomic and metabolic criteria for immunotherapy response assessment.
| Criteria | |||||
|---|---|---|---|---|---|
| Morphologic | CR | PR | SD | PD | New Lesions |
| RECIST 1.1 (2009) [6] | disappearance of all lesions | ≥30% decrease from baseline | Neither PR nor PD | ≥20% increase, minimum 5 mm | as progressive disease |
| irRC (2009) [7] | as RECIST 1.1 | ≥50% decrease from baseline | <50% decrease in tumor burden vs. baseline or <25% increase vs. nadir | ≥25% increase | incorporated into tumor burden; confirmed at least 4 weeks apart |
| irRECIST (2013) [8] | as RECIST 1.1 | as RECIST 1.1 | Neither PR nor PD | as RECIST 1.1 | same as irRC |
| iRECIST (2017) [9] | as RECIST 1.1 | as RECIST 1.1 | Neither PR nor PD | as RECIST 1.1 | iUPD, not incorporated into tumor burden; confirmed 4–12 weeks apart (iCPD) |
| imRECIST (2018) [10] | as RECIST 1.1 | as RECIST 1.1 | Neither PR nor PD | as RECIST 1.1 | same as irRC |
| Metabolic | CMR | PMR | SMD | PMD | New lesions |
| EORTC (1999) [11] | complete resolution of [18F]FDG uptake | reduction of a minimum of 15% ± 25% in tumor SUV after 1 cycle of chemotherapy, and >25% after more than one treatment cycle |
increase in SUV of less than 25% or a decrease of less than 15% | increase in tumor FDG uptake > 25%, increase of the maximum tumor > 20%, new metastases |
as progressive disease |
| PERCIST (2009) [12] | disappearance of all metabolically active lesions | SULpeak reduction ≥ 30% in the hottest target lesions | neither PMD nor PMR/CMR | SULpeak increase ≥ 30% in the hottest target lesion | as progressive disease |
| PERCIMT (2018) [13] | disappearance of all metabolically active lesions | disappearance of some but not all metabolic lesions and no new lesions | neither PMD nor PMR/CMR | 4 or more new lesions (<1 cm in diameter), or 3 or more new lesions (>1 cm in diameter), or 2 or more new lesions (>1.5 cm in diameter) |
according to the number and the diameter |
| imPERCIST (2019) [14] | same as PERCIST | same as PERCIST | neither PMD nor PMR/CMR | SULpeak increase ≥ 30% in the hottest target lesion | do not configure automatically PMD, incorporate in the sum of SULpeak |
| iPERCIST (2019) [15] | same as PERCIST | same as PERCIST | neither PMD nor PMR/CMR | SULpeak increase ≥ 30%, or new [18F]FDG-avid lesions (UPMD) |
need to be confirmed after 4–8 weeks (CPMD) |
| Combined criteria | Clinical benefit | No clinical benefit | |||
| PECRIT (2017) [16] | CR as per RECIST 1.1 (disappearance of all target lesions; reduction in short axis of target lymph nodes to <1 cm; no new lesions) |
PR as per RECIST 1.1 (decrease in target lesion diameter sum > 30%) |
Does not meet other criteria plus change in SUL peak of the hottest lesion of >15% |
Does not meet other criteria plus change in SUL peak of the hottest lesionof ≤15% |
PD as per RECIST 1.1 (increase in target lesion diameter sum of >20% and at least 5 mm or new lesions) |